Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034262 | 0.93 | KDM1A (0.47) | GPR119ALOX5APFEN1KDM1AJAK2 | |
| SCHEMBL16808869 | 0.90 | GPR119 (0.46) | GPR119ALOX5APFEN1EGLN2CHEK2 | |
| SCHEMBL17559065 | 0.81 | KDM1A (0.51) | KDM1A | |
| SCHEMBL30034274 | 0.79 | IDO1 (0.45) | GPR119KDM1AJAK2JAK3PTK2 | |
| SCHEMBL17427340 | 0.79 | KDM1A (0.49) | GPR119ALOX5APFEN1KDM1AEGLN2 | |
| SCHEMBL17432965 | 0.79 | ALOX5AP (0.46) | GPR119ALOX5APFEN1KDM1AEGLN2 | |
| SCHEMBL17427358 | 0.78 | KDM1A (0.52) | GPR119ALOX5APFEN1KDM1AEGLN2 | |
| SCHEMBL17559077 | 0.78 | KDM1A (0.43) | KDM1A | |
| SCHEMBL31071572 | 0.76 | GPR119 (0.53) | GPR119CHEK2 | |
| SCHEMBL24659688 | 0.76 | KDM1A (0.56) | GPR119KDM1AJAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885ALOX5AP 1897/4885FEN1 1152/4885 |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | GPR119 2640/4885ALOX5AP 1897/4885FEN1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.